Edition:
United States

VBI Vaccines Inc (VBIV.OQ)

VBIV.OQ on NASDAQ Stock Exchange Capital Market

4.18USD
15 Dec 2017
Change (% chg)

$0.08 (+1.95%)
Prev Close
$4.10
Open
$4.11
Day's High
$4.23
Day's Low
$4.11
Volume
949,116
Avg. Vol
63,280
52-wk High
$6.59
52-wk Low
$3.04

Latest Key Developments (Source: Significant Developments)

VBI Vaccines announces full exercise of option to purchase additional shares, upsized registered direct offering for proceeds of $71.9 mln
Monday, 30 Oct 2017 08:00am EDT 

Oct 30 (Reuters) - VBI Vaccines Inc -:VBI Vaccines announces full exercise of underwriters’ option to purchase additional shares and upsized registered direct offering for aggregate proceeds of $71.9 million.VBI Vaccines Inc - ‍in addition, VBI's previously announced concurrent registered direct offering was upsized from US$20.8 million to US$22.8 million​.  Full Article

VBI vaccines prices concurrent public offering and registered direct offering
Thursday, 26 Oct 2017 09:29am EDT 

Oct 26 (Reuters) - VBI Vaccines Inc :VBI Vaccines prices concurrent public offering and registered direct offering for aggregate proceeds of $63.5 million.Vbi Vaccines Inc - ‍pricing of offering at a price to public of US$3.05 per share​.  Full Article

VBI Vaccines announces proposed concurrent public offering
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - VBI Vaccines Inc ::VBI Vaccines announces proposed concurrent public offering and registered direct offering of common shares.VBI Vaccines- to use proceeds from offerings to fund pivotal phase III clinical program for SCI-B-VAC in U.S., Europe, Canada​.VBI Vaccines Inc - ‍ to also use proceeds from offerings for funding phase I/IIA clinical study of VBI-1901 for glioblastoma multiforme, among others.  Full Article

VBI Vaccines announces FDA acceptance of investigational NDA for sci-b-vac phase 3 clinical program
Wednesday, 30 Aug 2017 08:00am EDT 

Aug 30 (Reuters) - VBI Vaccines Inc :VBI Vaccines announces FDA acceptance of investigational new drug application for SCI-B-VAC(R) phase 3 clinical program.VBI Vaccines Inc - ‍expects to initiate enrollment in a phase 3 clinical program later in second half of 2017 in U.S., Europe and Canada​.  Full Article

VBI reports positive outcome from phase III pre-ind discussions with the FDA for hepatitis B vaccine
Monday, 19 Jun 2017 08:30am EDT 

June 19 (Reuters) - Vbi Vaccines Inc :Vbi vaccines reports positive outcome from phase iii pre-ind discussions with the fda for hepatitis b vaccine, sci-b-vac(tm).Vbi vaccines - vbi is now in process of preparing a phase iii ind for u.s., and ctas for europe and canada, with submission planned in h2 2017.Vbi vaccines inc - vbi plans to submit ind in second half of 2017, together with clinical trial applications ("ctas") for europe and canada.  Full Article

VBI Vaccines files for mixed shelf of up to $150 mln
Monday, 15 May 2017 09:17am EDT 

May 15 (Reuters) - VBI Vaccines Inc ::Files for mixed shelf of up to $150.0 million - sec filing.  Full Article

VBI Vaccines receives positive EMA scientific advice regarding Sci-B-Vac(TM) phase III clinical study
Tuesday, 7 Feb 2017 08:30am EST 

VBI Vaccines Inc - : Receives positive EMA scientific advice regarding Sci-B-Vac(TM) Phase III clinical study .Evaluating plans for pivotal phase III clinical studies with U.S. Food and Drug Administration (FDA) and Health Canada.  Full Article

Perceptive Advisors Llc reports 20.5 pct stake in VBI Vaccines Inc as of Dec. 6
Monday, 12 Dec 2016 06:21am EST 

Vbi Vaccines Inc :Perceptive Advisors Llc reports 20.5 percent stake in VBI Vaccines Inc as of December 6 -sec filing.  Full Article

VBI vaccines says Egidio Nascimento, has been named chief financial officer of company
Monday, 26 Sep 2016 04:30pm EDT 

VBI Vaccines Inc :Says Egidio Nascimento, has been named chief financial officer of company.  Full Article

VBI Vaccines to continue Phase I Trial of its CMV Vaccine Candidate
Monday, 22 Aug 2016 08:30am EDT 

Vbi Vaccines Inc : Data safety monitoring board has no objection to co continuing enrollment in phase i clinical study to evaluate preventative cytomegalovirus vaccine candidate .Says will continue to share clinical trial safety data with Health Canada periodically throughout study.  Full Article

BRIEF-VBI Vaccines adds Ran Nussbaum to board

* Vbi vaccines strengthens board of directors with appointment of ran nussbaum Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)